Wagner, S. A., Desjardins, A., Reardon, D. A., Marcello, J., Herndon, J. E., Quinn, J. A., … Vredenburgh, J. J. (2008). Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. Journal of Clinical Oncology, 26(15_suppl), 2021–2021. https://doi.org/10.1200/jco.2008.26.15_suppl.2021

Wagner, S. A., A. Desjardins, D. A. Reardon, J. Marcello, J. E. Herndon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, H. S. Friedman, and J. J. Vredenburgh. “Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2021–2021. https://doi.org/10.1200/jco.2008.26.15_suppl.2021.

Wagner SA, Desjardins A, Reardon DA, Marcello J, Herndon JE, Quinn JA, et al. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. Journal of Clinical Oncology. 2008 May 20;26(15_suppl):2021–2021.

Wagner, S. A., et al. “Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 2021–2021. Crossref, doi:10.1200/jco.2008.26.15_suppl.2021.

Wagner SA, Desjardins A, Reardon DA, Marcello J, Herndon JE, Quinn JA, Rich JN, Sathornsumetee S, Friedman HS, Vredenburgh JJ. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):2021–2021.